Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, and Soupline to a range of traditional and eCommerce retailers, wholesalers, and distributors. It includes pharmaceutical products for dentists and other oral health professionals. Its Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Colgate-Palmolive Company

The Procter & Gamble Company PG has long relied on emerging markets such as Latin America, Asia and Africa as growth engines for its global business. These regions offer large populations and rising middle-class consumers, making them an attractive focus for the company’s strategy. However, with signs of slowing global demand, questions are being raised about whether PG can maintain its strong momentum in these markets.
Despite global headwinds, Procter & Gamble’s recent results showed that emerging markets continue to deliver solid performance. In the latest quarter, the company saw volume growth in Latin America and India, supported by strong brand presence and effective pricing strategies. Management also emphasized that their long-term focus on affordability, innovation and expanding distribution helps them adapt to varying economic conditions in these regions. This suggests that PG is still well-positioned to capture growth, even if overall global demand weakens.
Looking ahead, the real challenge for Procter & Gamble will be balancing short-term pressures with long-term opportunities. If consumer spending slows further, the company may need to adjust its pricing and promotional strategies to stay competitive while protecting margins. However, PG’s diversified portfolio and strong execution in emerging markets provide a buffer against softer demand in developed economies. In short, while slowing global demand poses risks, the company’s emerging market strategy remains resilient and focused on sustainable growth.
PG’s Peers: How CHD & CL Navigate Slowing Global Demand
In today’s inflationary and volatile environment, both Church & Dwight CHD and Colgate-Palmolive Company CL are navigating slowing global demand with strategic discipline.
Church & Dwight has shown resilience in a volatile environment by leveraging its strong portfolio of value and premium brands while continuing to grow internationally. In second-quarter 2025, its international business delivered 5% organic sales growth, led by HERO, Therabreath and Femfresh, with share gains across all power brands. Despite soft U.S. demand and tariff pressures, CHD’s strategy of balancing affordability with innovation, coupled with disciplined marketing investment, has helped sustain momentum in emerging markets, where it continues to expand brand penetration and online sales.
Colgate remains focused on its emerging market strategy by driving premium innovation, pricing and brand health despite softer category growth and foreign exchange headwinds. In second-quarter 2025, Latin America and Africa/Eurasia delivered organic growth supported by premium toothpaste launches and personal care relaunches. However, the Asia-Pacific faced weakness in India and China retail, while it witnessed strength in premium innovation like Colgate Miracle Repair. By combining pricing actions with continued investment in brand building and local innovation, Colgate is working to sustain household penetration in key emerging markets, even as slowing global demand poses challenges.
PG’s Price Performance, Valuation & Estimates
Procter & Gamble’s shares have lost around 5.5% year to date compared with the industry’s 4.7% dip.
Image Source: Zacks Investment Research
From a valuation standpoint, PG trades at a forward price-to-earnings ratio of 22.47X compared with the industry’s average of 20.17X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for PG’s fiscal 2025 and 2026 EPS indicates year-over-year growth of 2.3% and 6.3%, respectively. The company’s EPS estimates for fiscal 2025 and 2026 have moved downward in the past 30 days.
Image Source: Zacks Investment Research
Procter & Gamble currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will Slowing Global Demand Dent PG's Emerging Market Strategy?

Below is Validea's guru fundamental report for COLGATE-PALMOLIVE CO (CL). Of the 22 guru strategies we follow, CL rates highest using our Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
COLGATE-PALMOLIVE CO (CL) is a large-cap growth stock in the Personal & Household Prods. industry. The rating using this strategy is 68% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of COLGATE-PALMOLIVE CO
More Information on Warren Buffett
About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men. (Forbes puts his net worth at $37 billion.) Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards. His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.
Additional Research Links
Harry Browne Permanent Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CL Quantitative Stock Analysis - Warren Buffett

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores?
The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value Score
Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth Score
Growth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
What if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.75% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Colgate-Palmolive (CL)
Colgate-Palmolive Company’s business strategy closely defines efforts to increase its leadership in key product categories through innovation in core businesses, tracking adjacent categories growth and expansion into new markets and channels. Due to the shift of consumer preference to organic and natural ingredients, the company is expanding its Naturals range, including Naturals toothpaste. It is ranked as a leading consumer goods company with a global household penetration.
CL is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. CL has a Growth Style Score of B, forecasting year-over-year earnings growth of 2.2% for the current fiscal year.
Seven analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.03 to $3.68 per share. CL boasts an average earnings surprise of +3.7%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, CL should be on investors' short list.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Colgate-Palmolive (CL) is a Top Growth Stock for the Long-Term

Colgate-Palmolive Company’s CL innovation strategy for 2025 is tightly linked to its ambition to boost market share despite ongoing macroeconomic and category growth challenges. The company is leaning heavily into impactful innovation as a key building block for long-term growth, pairing it with data analytics, AI and omni-channel demand generation to accelerate its 2030 strategic plan. Across regions, Colgate is introducing core and premium products that not only strengthen brand health but also expand household penetration. For instance, in oral care, launches like Colgate Max White Clinical in the U.K. and Miracle Repair serum-infused toothpaste in China are being positioned at strategic price points to attract new users while reinforcing the company’s premium credentials.
This innovation drive is not limited to oral care but extends across personal and home care as well as Hill’s Pet Nutrition. In Europe, personal care offerings like Sanex Skin Therapy with Amino Acid Complex are addressing specific skin needs, while in Latin America, relaunches of the Protex bar soap and Suavitel Superior Care fabric conditioner are designed to strengthen category leadership. In Hill’s Pet Nutrition segment, science-led innovations, such as ActivBiome+ Multi-Benefit in Science Diet and new Prescription Diet formulas, target niche therapeutic needs, appealing to veterinarians and pet owners seeking specialized nutrition solutions.
Colgate’s approach is also rooted in premiumization, elevating its product mix to capture higher-margin sales while differentiating from value-tier competitors. Brands like Colgate Total, Luminous White, Sensitive Pro Relief and elmex are leading premium growth, particularly in markets like Latin America and Europe, where consumers continue to trade up for performance and specialized benefits. These premium launches are supported by robust advertising investment, which remains over 13% of net sales, reinforcing consumer awareness and trust at a time when competitive activity is intense.
Looking ahead, the company’s 2025 guidance acknowledges weaker category growth in the first half and potential headwinds from raw material inflation. However, management expects the combination of innovation-led volume gains, targeted pricing strategies and productivity-driven reinvestment to help offset these pressures. If executed effectively, Colgate’s innovation pipeline, spanning oral care breakthroughs, personal and home care upgrades, and advanced pet nutrition, could serve as the primary catalyst for market share gains in 2025, solidifying its competitive positioning in both mature and emerging markets.
CL’s Competition in the Global Arena
Church & Dwight Co. Inc. CHD, The Procter & Gamble Company PG and The Clorox Company CLX are key companies competing with Colgate in theglobal market
Church & Dwight is driving growth through innovation in both premium and value segments, highlighted by the Touchland acquisition in hand sanitizers, Batiste Light in dry shampoo, the Therabreath mouthwash expansion, and HERO’s Mighty Patch Body launch. These initiatives, along with rising online sales, aim to boost household penetration and brand share despite category and retailer headwinds for Church & Dwight.
Procter & Gamble is leveraging its “irresistible superiority” strategy with launches like Tide evo plastic-free detergent, Swiffer Sweep and Mop Deluxe, Pampers premium upgrades, and SK-II’s LXP line. Digital-first marketing and a strong track record in top new product rankings underpin Procter & Gamble’s ability to grow categories and outpace competitors.
Clorox is advancing innovation across its portfolio to support long-term growth, focusing on value-driven offerings and sustainability. In cleaning, the company is rolling out bleach innovations with enhanced disinfection claims while expanding Burt’s Bees into new lip and skin care formats. Clorox is also innovating in Glad trash bags with stronger, more sustainable materials and launching Brita products with improved filtration performance. These initiatives aim to strengthen brand relevance, capture new users and reinforce category leadership amid a competitive and cost-sensitive environment.
See our %%CTA_TEXT%% report – free today!
7 Best Stocks for the Next 30 Days
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Will Colgate's Innovation Drive Market Share Gains in 2025?

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Consumer Staples Select Sector SPDR Fund (Symbol: XLP) where we have detected an approximate $259.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 198,571,809 to 201,721,809). Among the largest underlying components of XLP, in trading today Philip Morris International Inc (Symbol: PM) is down about 1.4%, Altria Group Inc (Symbol: MO) is down about 0.1%, and Colgate-Palmolive Co. (Symbol: CL) is relatively unchanged. For a complete list of holdings, visit the XLP Holdings page » The chart below shows the one year price performance of XLP, versus its 200 day moving average:
Looking at the chart above, XLP's low point in its 52 week range is $75.605 per share, with $84.53 as the 52 week high point — that compares with a last trade of $82.48. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Top Ten Hedge Funds Holding RW
LOGI Historical Stock Prices
HAWK Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Inflows: XLP, PM, MO, CL

At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2025 reporting period, and noticed that Colgate-Palmolive Co. (Symbol: CL) was held by 12 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen.
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in CL positions, for this latest batch of 13F filers:
Aggregate Change:
+491,177
+$42,092
In terms of shares owned, we count 6 of the above funds having increased existing CL positions from 03/31/2025 to 06/30/2025, with 3 having decreased their positions.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the CL share count in the aggregate among all of the funds which held CL at the 06/30/2025 reporting period (out of the 3,299 we looked at in total). We then compared that number to the sum total of CL shares those same funds held back at the 03/31/2025 period, to see how the aggregate share count held by hedge funds has moved for CL. We found that between these two periods, funds reduced their holdings by 1,661,648 shares in the aggregate, from 65,224,504 down to 63,562,856 for a share count decline of approximately -2.55%. The overall top three funds holding CL on 06/30/2025 were:
»
Fund
Shares of CL Held
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Colgate-Palmolive Co. (Symbol: CL).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

See Which Of The Latest 13F Filers Holds CL

The all-important Employment Situation report for July — nonfarm payrolls and unemployment — is out this morning, and results are far below projections: +73K new jobs were filled last month, lower than the +100K expected. The Unemployment Rate ticked up 10 basis points (bps) to 4.2%, which is still historically very good.
The initial takeaway from this report is the massive downward revisions to the prior two months: June dialed way back from +147K to 14K — including only +3K new jobs in the private sector — and May from +144K to +19K. The trailing 4-month average in nonfarm payrolls is now around -100K fewer per month than the prior 4 months. In short, it’s a much weaker labor market this morning than we knew yesterday.
Hourly Wages still rose +0.3% for the month, as expected, up from +0.2% in June. Year over year, wages are +3.9%, up 10 bps from expectations, and +20 bps month over month. The Average Workweek ticked up to a still-lowish 34.3, but Labor Force Participation fell to 62.2% — not a strong number. The U-6 (aka "real unemployment") dipped a tad to 7.9%, relatively in-line with the historical average.
Let’s address the Unemployment Rate a moment: at 4.2%, the appearance is that a satisfactory number of Americans are still gainfully employed. However, with retirees in both the Baby Boomer and now Generation X populations averaging around 90-100K per month, many in the workforce would take their most recent pink slip and not become part of the employed, but part of the newly retired. Thus, unemployment in the low 4% range may be a bit of a false indicator.
By sector, Healthcare brought in +55K new jobs last month — far and away the strongest industry for jobs currently. Social assistance gathered +18K. Manufacturing, on the other hand, spent its third straight month in negative territory, -37K, and the Federal Government has cut payrolls by -12K. Since President Trump has taken office in this term, the federal government workforce has shed -84K jobs.
Pre-Markets, Bond Yields Down; Fed Cut Probability Way Up
The timing of this jobs report in relation to the latest Fed meeting could have been better. When the Fed decided on Wednesday not to cut interest rates from their current +4.25-4.50% level, it was with the understanding the labor market had created +258K more jobs than we currently recognize. There is no Fed meeting in August — only an emergency meeting to cut rates would beget relief on interest rates before the next scheduled meeting in mid-September.
Depending on how the labor market performs over the next month and a half — not to mention what we see from the Inflation Rate and PCE reports (+2.7% and +2.6%, respectively, higher than previous months) — we may see a 25 bps or even a 50 bps rate cut come September. The likelihood of a cut ramped way up this morning, from around +34% ahead of the jobs report to +87% now.
The bond market has taken notice: the 10-year bond yield has fallen to +4.27%, more than half a percentage point since earlier this morning, and similarly on the 2-year, now +3.79%. Meanwhile, pre-market trading has sent major indexes into the red: the Dow is -330 points at this hour, the S&P 500 is -53 and the Nasdaq -220.
Q2 Earnings Friday Morning, at a Glance: XOM, CL & More
ExxonMobil XOM posted mixed results in its Q2 report ahead of today’s opening bell. Earnings of $1.64 per share outshined the $1.49 analysts were expecting, for a +10% positive earnings surprise. Revenues, however, came in -1.59% below estimates. Oil supermajor rival Chevron CVX also beat earnings expectations, by +4% to $1.77 per share.
Colgate-Palmolive CL posted a 3-cent beat to 92 cents per share in its Q2 earnings report this morning, while beating on the top line by +1.17%. Dupixent maker Regeneron REGN had perhaps the biggest earnings beat of the morning, +60.5% to $12.89 per share in the quarter.
What to Expect from the Stock Market Today
We’re not done with economic reports this Friday. S&P Manufacturing PMI for July is predicted to inch up month over month to 49.9 from 49.5 previously. This would bring this metric just to the precipice of growth, which is the 50 level. ISM Manufacturing, also for July, is expected to rise to 49.5% from 49.0% reported a month ago.
Construction Spending for June, Auto Sales for July and the final Consumer Sentiment print for July all come out after the regular trading day starts, as well. Construction spending is expected to improve but still show a negative -0.1%, while Consumer Sentiment is projected to meet the prior read of 61.8 — a good number.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Nonfarm Payrolls Come in SIgnificantly Below Expectations

Colgate-Palmolive (CL) reported $5.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 1%. EPS of $0.92 for the same period compares to $0.91 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $5.05 billion, representing a surprise of +1.17%. The company delivered an EPS surprise of +3.37%, with the consensus EPS estimate being $0.89.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales- Oral, Personal and Home Care- North America: $1.03 billion versus $1.01 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.
Net Sales- Oral, Personal and Home Care- Latin America: $1.21 billion versus $1.24 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.
Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $295 million versus $277.3 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.
Net Sales- Oral, Personal and Home Care- Asia Pacific: $687 million versus $666.6 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.
Net Sales- Oral, Personal and Home Care- Europe: $738 million versus $716.03 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.
Net Sales- Pet Nutrition: $1.16 billion compared to the $1.13 billion average estimate based on four analysts. The reported number represents a change of +3.9% year over year.
Net Sales- Total Oral, Personal and Home Care: $3.95 billion versus $3.91 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.3% change.
Operating profit- Total Oral, Personal and Home Care: $997 million versus $999.32 million estimated by two analysts on average.
Operating profit- Corporate: $-181 million versus $-173.54 million estimated by two analysts on average.
Operating profit- Pet Nutrition: $264 million versus the two-analyst average estimate of $260.59 million.
Shares of Colgate-Palmolive have returned -9.6% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Compared to Estimates, Colgate-Palmolive (CL) Q2 Earnings: A Look at Key Metrics

Colgate-Palmolive (CL) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.91 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.37%. A quarter ago, it was expected that this consumer products maker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of +5.81%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Colgate-Palmolive, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $5.11 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.17%. This compares to year-ago revenues of $5.06 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Colgate-Palmolive shares have lost about 7.8% since the beginning of the year versus the S&P 500's gain of 7.8%.
What's Next for Colgate-Palmolive?
While Colgate-Palmolive has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Colgate-Palmolive was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.91 on $5.18 billion in revenues for the coming quarter and $3.67 on $20.32 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, BJ's Wholesale Club (BJ), has yet to report results for the quarter ended July 2025. The results are expected to be released on August 22.
This wholesale membership warehouse operator is expected to post quarterly earnings of $1.10 per share in its upcoming report, which represents a year-over-year change of +0.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
BJ's Wholesale Club's revenues are expected to be $5.47 billion, up 5.2% from the year-ago quarter.
Should You Invest in Colgate-Palmolive Company (CL)?
Before you invest in Colgate-Palmolive Company (CL), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	CL	Industry	CL	Industry	Volume, $
Yesterday 85.3 - 87.3	1.23	7.53	39.76	0.52	237.31M
Week 84.3 - 87.9	3.09	13.04	1.46	5.09	1.68B
Month 82.4 - 89.2	-1.38	15.81	3.35	13.94	6.32B
3 Months 82.4 - 94.2	-4.67	33.22	9.12	19.40	19.87B
6 Months 82.4 - 100.2	-1.64	27.96	13.62	29.58	38.21B
Year 82.4 - 109.3	-15.98	40.85	20.66	37.00	65.68B
3 years 67.6 - 109.3	7.94	59.17	30.70	66.79	166.86B
5 years 67.6 - 109.3	11.20	44.49	39.25	95.94	272.58B
All time 16.3 - 109.3	428.68	127.97	—	—	251.09B

Colgate-Palmolive Company

Price and volatility history

Risk ratios